Arrowhead Pharmaceuticals (ARWR) Consolidated Net Income: 2010-2025
Historic Consolidated Net Income for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $16.1 million.
- Arrowhead Pharmaceuticals' Consolidated Net Income rose 109.30% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 104.93%. This contributed to the annual value of $30.1 million for FY2025, which is 104.94% up from last year.
- Latest data reveals that Arrowhead Pharmaceuticals reported Consolidated Net Income of $16.1 million as of Q3 2025, which was up 109.02% from -$178.7 million recorded in Q2 2025.
- In the past 5 years, Arrowhead Pharmaceuticals' Consolidated Net Income ranged from a high of $367.8 million in Q1 2025 and a low of -$178.7 million during Q2 2025.
- Moreover, its 3-year median value for Consolidated Net Income was -$127.0 million (2024), whereas its average is -$67.9 million.
- Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 366.37% in 2024, then soared by 389.63% in 2025.
- Arrowhead Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$62.9 million in 2021, then soared by 33.50% to -$41.8 million in 2022, then slumped by 223.78% to -$135.4 million in 2023, then declined by 29.43% to -$175.2 million in 2024, then surged by 109.30% to $16.1 million in 2025.
- Its Consolidated Net Income was $16.1 million in Q3 2025, compared to -$178.7 million in Q2 2025 and $367.8 million in Q1 2025.